

**MINUTES**  
**INSTITUTIONAL BIOSAFETY COMMITTEE**  
**DATE: May 8, 2026**

**Attendance:** Total Attending: 8

**Voting Members Present:** 7

**Called to Order:** 10:00 a.m.

<b>Name</b>	<b>Expertise</b>	<b>Present</b>
Linda Cassidy, MS	Non-Voting Member	X
Sue Gotta, MS	rDNA; Select Agents	X
Gerald Grunwald, PhD	rDNA; Biochemistry; Cellular & Developmental Biology	
Douglas C. Hooper, PhD	rDNA; Immunology; Gene Transfer	X
Botond Igyarto, PhD	Microbiology	X
Loretta Kelly, Esq.	Non-affiliate Community Member	X
Kathleen "Kitty" Kono	Non-Affiliate Community Member	X
Phil LaTourette, DVM	Laboratory Animal Sciences	
Sara Meyer, PhD	Cancer Biology	
Fabienne Paumet, PhD	Cellular Biology & Biochemistry	
Drake Stierman	Safety Officer	X
Megan Watson, MS	Lab Specialist	X

**MINUTES REVIEWED:**

Minutes of the April 10, 2026 meeting were presented for review.

Motion to Approve: Douglas C. Hooper

Seconded: Loretta Kelly

Total = 7; For-7, Opposed-0, Abstained-0

**NEW PROTOCOLS:**

**1. Principal Investigator S.R.**

IBC Control# 26-04-1026

**Summary:**

- This protocol is for a neurosurgical biorepository with stored human tissues and blood.
- The principal risk identified was:
  - Human samples
- Containment has been set to BSL-2.

**Committee Review:**

- This protocol did not involve either recombinant or synthetic DNA.
- The risks were adequately identified by the Principal Investigator and appropriate mitigation was described in the protocol.
- No clarifications were requested.
- A motion was made and seconded to approve this protocol. The motion was unanimously approved.

**ADMINISTRATIVELY APPROVED ITEMS:**

The KSI database indicates the following items have been given administrative approval since our last meeting:

**May 8, 2026**

Protocol #	PI - Initials	Form type	Comments
23-08-712	NL	New	Submittal of previously approved work; Changed PI from JS to NL
23-08-710	NL	Amendment	Changed PI from JS to NL
23-08-711	NL	Amendment	Changed PI from JS to NL
21-12-462-1	SM	Continuing Review	Active - updated personnel
23-07-701	LS	Continuing Review	Active - updated personnel
25-03-934	ZS	Continuing Review	Active - added human cells & plasmids, updated personnel
25-08-973	MD	Amendment	Updated Clinical Protocol, clinical trial
25-04-945	MS	Amendment	Updated personnel and Clinical Protocols, clinical trial
23-04-675-1	FP	Continuing Review	Active - updated personnel only, 3 yr review
25-12-1002	SS	New	Submittal of previously approved work
22-03-493-1	AS	Continuing Review	Active - updated personnel
24-04-832	SG	Continuing Review	Active - updated personnel, Clinical Protocol, IB, & Pharm Manual
21-06-392-1	AL	Continuing Review	Active - no updates
25-04-945	MS	Amendment	Updated summary of protocol, clinical trial
24-04-829	ZR	Continuing Review	Active - no updates
22-03-490-1	DA	Amendment	Added hazardous materials and updated corresponding pages

**OTHER BUSINESS:**

- An updated version of the IBC Policy & Procedure Manual was distributed to the committee asking for feedback. This will be discussed at the June meeting.
- Clinical trials that are industry sponsored are considered being reviewed by a Central IBC. We are currently investigating the creation of a registration form in our IBC database to track these trials.
- Our 6<sup>th</sup> floor ABL3 lab should be up and running the first week of June. The 3<sup>rd</sup> floor ABL3 and 5<sup>th</sup> floor BL3 labs hope to be commissioned in July.

Meeting Adjourned: 10:10 a.m.

Respectfully submitted for the IBC,

/s/Sue Gotta, MS  
Vice Chair, Institutional Biosafety Committee

SG/lc